298 related articles for article (PubMed ID: 35020045)
1. Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada.
Leung J; Chan G; Stjepanović D; Chung JYC; Hall W; Hammond D
Psychopharmacology (Berl); 2022 May; 239(5):1509-1519. PubMed ID: 35020045
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and forms of cannabis use in legal vs. illegal recreational cannabis markets.
Goodman S; Wadsworth E; Leos-Toro C; Hammond D;
Int J Drug Policy; 2020 Feb; 76():102658. PubMed ID: 31927413
[TBL] [Abstract][Full Text] [Related]
3. Trends in the use of cannabis products in Canada and the USA, 2018 - 2020: Findings from the International Cannabis Policy Study.
Hammond D; Goodman S; Wadsworth E; Freeman TP; Kilmer B; Schauer G; Pacula RL; Hall W
Int J Drug Policy; 2022 Jul; 105():103716. PubMed ID: 35613480
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Cannabis Use Disorder and Reasons for Use Among Adults in a US State Where Recreational Cannabis Use Is Legal.
Lapham GT; Matson TE; Bobb JF; Luce C; Oliver MM; Hamilton LK; Bradley KA
JAMA Netw Open; 2023 Aug; 6(8):e2328934. PubMed ID: 37642968
[TBL] [Abstract][Full Text] [Related]
5. Legal status of recreational cannabis and self-reported substitution of cannabis for opioids or prescription pain medication in Canada and the United States.
Wadsworth E; Hines LA; Hammond D
Subst Abus; 2022; 43(1):943-948. PubMed ID: 35420977
[No Abstract] [Full Text] [Related]
6. Cannabis Use for Endometriosis: Clinical and Legal Challenges in Australia and New Zealand.
Sinclair J; Toufaili Y; Gock S; Pegorer AG; Wattle J; Franke M; Alzwayid MAKM; Abbott J; Pate DW; Sarris J; Armour M
Cannabis Cannabinoid Res; 2022 Aug; 7(4):464-472. PubMed ID: 34978929
[No Abstract] [Full Text] [Related]
7. Cannabis use for symptom relief in multiple sclerosis: A cross-sectional survey of webinar attendees in the US and Canada.
Hildebrand A; Minnier J; Cameron MH
Mult Scler Relat Disord; 2020 Feb; 38():101516. PubMed ID: 31855842
[TBL] [Abstract][Full Text] [Related]
8. Reasons for Purchasing Cannabis From Illegal Sources in Legal Markets: Findings Among Cannabis Consumers in Canada and U.S. States, 2019-2020.
Goodman S; Wadsworth E; Hammond D
J Stud Alcohol Drugs; 2022 May; 83(3):392-401. PubMed ID: 35590180
[TBL] [Abstract][Full Text] [Related]
9. The impact of legalization of access to recreational Cannabis on Canadian medical users with Cancer.
Hawley P; Gobbo M; Afghari N
BMC Health Serv Res; 2020 Oct; 20(1):977. PubMed ID: 33109169
[TBL] [Abstract][Full Text] [Related]
10. Synthetic cannabinoid poisonings and access to the legal cannabis market: findings from US national poison centre data 2016-2019.
Klein TA; Dilley JA; Graves JM; Liebelt EL
Clin Toxicol (Phila); 2022 Sep; 60(9):1024-1028. PubMed ID: 35942512
[TBL] [Abstract][Full Text] [Related]
11. Perceptions of cannabis use risk to mental health among youth in Canada, England and the United States from 2017 to 2021.
Lemos MK; Taylor E; Wadsworth E; Reid JL; Hammond D; East K
Drug Alcohol Depend; 2023 Sep; 250():110904. PubMed ID: 37549543
[TBL] [Abstract][Full Text] [Related]
12. Adverse outcomes of cannabis use in Canada, before and after legalisation of non-medical cannabis: cross-sectional analysis of the International Cannabis Policy Study.
Marquette A; Iraniparast M; Hammond D
BMJ Open; 2024 Jan; 14(1):e077908. PubMed ID: 38171626
[TBL] [Abstract][Full Text] [Related]
13. Prices and Purchase Sources for Dried Cannabis Flower in the United States, 2019-2020.
Wadsworth E; Driezen P; Pacula RL; Kilmer B; Hammond D
Cannabis Cannabinoid Res; 2023 Oct; 8(5):923-932. PubMed ID: 35363550
[No Abstract] [Full Text] [Related]
14. Prevalence and correlates of non-medical only compared to self-defined medical and non-medical cannabis use, Canada, 2015.
Rotermann M; Pagé MM
Health Rep; 2018 Jul; 29(7):3-13. PubMed ID: 30020531
[TBL] [Abstract][Full Text] [Related]
15. Differences in patterns of cannabis use among youth: Prevalence, perceptions of harm and driving under the influence in the USA where non-medical cannabis markets have been established, proposed and prohibited.
Wadsworth E; Hammond D
Drug Alcohol Rev; 2018 Nov; 37(7):903-911. PubMed ID: 29992695
[TBL] [Abstract][Full Text] [Related]
16. Cannabis advertising, promotion and branding: Differences in consumer exposure between 'legal' and 'illegal' markets in Canada and the US.
Rup J; Goodman S; Hammond D
Prev Med; 2020 Feb; 133():106013. PubMed ID: 32027914
[TBL] [Abstract][Full Text] [Related]
17. Are recreational cannabis laws associated with declining medical cannabis program enrollment in the U.S.? An analysis of cardholder enrollment and demographic characteristics from 2013 to 2020.
Okey SA; Castro SA; Waddell JT; Jones CB; Blake AJ; O'Rourke HP; Davis MC; Meier MH
Int J Drug Policy; 2022 Feb; 100():103531. PubMed ID: 34818602
[TBL] [Abstract][Full Text] [Related]
18. Consumer Experiences with Delta-8-THC: Medical Use, Pharmaceutical Substitution, and Comparisons with Delta-9-THC.
Kruger DJ; Kruger JS
Cannabis Cannabinoid Res; 2023 Feb; 8(1):166-173. PubMed ID: 34797727
[No Abstract] [Full Text] [Related]
19. Declared Rationale for Cannabis Use Before and After Legalization for Nonmedical Use: A Longitudinal Study of Community Adults in Ontario.
AminiLari M; Busse JW; Turna J; MacKillop J
Cannabis Cannabinoid Res; 2023 Dec; 8(6):1133-1139. PubMed ID: 35333612
[No Abstract] [Full Text] [Related]
20. Prevalence and correlates of medical cannabis patients' use of cannabis for recreational purposes.
Morean ME; Lederman IR
Addict Behav; 2019 Jun; 93():233-239. PubMed ID: 30772776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
